WAY

TentativeAI Memo

Waystar

As of 2026-05-05/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-05 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Action

—

Confidence

low

Horizon

—

Key catalyst

Iodine integration and AI product rollout could become the next proof point • 2026-09-30

Expected move: +25%

Biggest risk

The bear read is that part of recent retention strength still reflects fallout from a competitor cybersecurity incident, NRR eased to 110.5% from 113.5%, volume-based revenue grew only 7.3%, and investors may wait for clearer organic-post-acquisition evidence before paying up.

Invalidation

Break below $16 or thesis failure.

What would change my mind?

The cleanest bull read is that Q1 kept growth quality high: revenue grew 22%, subscription revenue outgrew total revenue, EBITDA margin stayed strong, and client metrics remained healthy, which supports a software-compounder framing if AI and Iodine add incremental upsell.

Research note

Recommendation

—

Confidence

low

As of

2026-05-05

Base target

$27

p=50%

Bull target

$34

p=25%

Bear target

$16

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 execution and FY26 outlook keep the core growth case intact
Mix shift toward subscription software can support a higher-quality revenue base
The cleanest bull read is that Q1 kept growth quality high: revenue grew 22%, subscription revenue outgrew total revenue, EBITDA margin stayed strong, and client metrics remained healthy, which supports a software-compounder framing if AI and Iodine add incremental upsell.

BearKey bullets

Execution on the Iodine acquisition is still a key swing factor; the company explicitly flags acquisition integration risk in its filings.
Net revenue retention fell to 110.5% from 113.5%, and the 10-Q says both periods include benefit from unusually high win rates and faster implementations tied to a competitor cybersecurity incident, making normalization a live risk.
Peer evidence in the packet is mostly broad health-care equipment and services exposure rather than direct revenue-cycle software comps, limiting confidence in relative valuation support.

WatchKey bullets

Iodine integration and AI product rollout could become the next proof point

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $27 (p=50%)

Bull/Bear spread: +58% / -26%

Vs latest close: Bull +58% · Base +25% · Bear -26%

Scenario probabilities

Bull Target: $34 (p=25%)Base Target: $27 (p=50%)Bear Target: $16 (p=25%)

Commentary

Primary-source evidence is solid, but the forward setup remains a cautious monitoring view: the company posted a strong quarter, yet the May 4, 2026 anchor price of $20.88 suggests the market has not fully re-rated the story after earnings. Recent news flow is earnings-related, but post-print analyst revision data is sparse and the peer set is not direct enough to support a standard-conviction thesis.

As of 2026-05-05 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 execution and FY26 outlook keep the core growth case intact
Mix shift toward subscription software can support a higher-quality revenue base

Scenarios

Bull Target (Scenario probability)

$34 / p=25% prob

Base Target (Scenario probability)

$27 / p=50% prob

Bear Target (Scenario probability)

$16 / p=25% prob

Price $22 as of 2026-07-23

Nearest Scenario: Base (∆ 25%)

Targets vs latest close: Bull +58% · Base +25% · Bear -26%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-30
Iodine integration and AI product rollout could become the next proof point
Management said it advanced the Iodine integration and launched an AI-powered recoupment solution, while the 10-Q frames Iodine as a strategic AI and revenue-cycle asset; evidence of cross-sell or faster monetization would matter because the stock still lacks a clear post-acquisition re-rating signal [#8-K-2026-04-29] [#10-Q-2026-04-29].
Prob 45.00% • Move 14.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Q1 execution and FY26 outlook keep the core growth case intact
2026-08-05
Waystar reported Q1 2026 revenue of $313.9M, up 22.4% year over year, with subscription revenue up 37.7% to $172.2M, adjusted EBITDA margin of 43%, 1,433 clients contributing over $100k in LTM revenue, and FY26 guidance of $1.274B-$1.294B revenue plus $530M-$540M adjusted EBITDA [#8-K-2026-04-29] [#10-Q-2026-04-29].
Prob 75% • Move 9% • Priced-in 60%

Long-term Catalysts

Months to a year

Mix shift toward subscription software can support a higher-quality revenue base
2026-12-31
The quarter showed subscription revenue reaching 54.9% of sales versus 48.8% a year earlier, while the filing emphasizes recurring provider-count fees, cross-sell potential, and network-effect data advantages; sustained mix improvement would support a better multiple if retention and volume trends hold [#10-Q-2026-04-29].
Prob 60% • Move 18% • Priced-in 35%

Risks

Execution on the Iodine acquisition is still a key swing factor; the company explicitly flags acquisition integration risk in its filings.
Net revenue retention fell to 110.5% from 113.5%, and the 10-Q says both periods include benefit from unusually high win rates and faster implementations tied to a competitor cybersecurity incident, making normalization a live risk.
Peer evidence in the packet is mostly broad health-care equipment and services exposure rather than direct revenue-cycle software comps, limiting confidence in relative valuation support.
The business remains tied to provider growth and healthcare transaction volumes, so slower client expansion, weaker utilization, or longer implementations could pressure volume-based growth.
Waystar still carries about $1.48B of outstanding debt, with meaningful exposure to SOFR-based financing despite hedges, so rates and leverage remain important to equity sensitivity.

Peers

Symbol	Summary
IRTC	iRhythm is a similar market-cap health-care name from the packet, but it is a cardiac-monitoring device company rather than a healthcare payments and revenue-cycle software platform, so it should not be used as a direct valuation anchor.
CHE	Chemed is a similar-size health-care-services company from the packet, but its hospice and plumbing-service exposure is not a clean operating comp for Waystar's recurring software and transaction-volume model.
BLCO	Bausch + Lomb provides only broad health-care-equipment sector context; it is not a direct comparator for Waystar, which keeps the peer read loose and the memo in monitoring mode.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-05

AI Stock Memo: WAY - Waystar - RankAlpha